FDA is notifying health care professionals and patients of this new safety information, and that frequent liver test monitoring is necessary to identify worsening liver function and ensure appropriate discontinuation of Ocaliva.
Serious Liver Injury Being Observed In Patients Without Cirrhosis Taking Ocaliva to Treat Primary Biliary Cholangitis
Previous
Previous
A devastating nerve disease stalks a mountain village with possible link to false morel consumption
Next
Next